The novel metabotropic glutamate receptor agonist 2R,4R-APDC potentiates stimulation of phosphoinositide hydrolysis in the rat hippocampus by 3,5-dihydroxyphenylglycine: evidence for a synergistic interaction between group 1 and group 2 receptors
- PMID: 9076745
- DOI: 10.1016/s0028-3908(96)00121-9
The novel metabotropic glutamate receptor agonist 2R,4R-APDC potentiates stimulation of phosphoinositide hydrolysis in the rat hippocampus by 3,5-dihydroxyphenylglycine: evidence for a synergistic interaction between group 1 and group 2 receptors
Abstract
The mGlu receptor subtypes and second messenger pathways that mediate 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) responses in brain tissues are not fully understood. 1S,3R-ACPD differs from 3,5-dihydroxyphenylglycine (DHPG) or quisqualate in that 1S,3R-ACPD also activates group 2 mGlu receptors (mGlu2 and mGlu3) that are negatively linked to cAMP formation. To investigate the contribution of group 2 mGlu receptor activity of 1S,3R-ACPD to the phosphoinositide response in the rat hippocampus, we examined the effects of the novel group 2 mGlu receptor agonist 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC). 2R,4R-APDC did not activate or inhibit group 1 mGlu receptors (human mGlu1 alpha and mGlu5a) or group 3 mGlu receptors (human mGlu4 and mGlu7), but potently decreased forskolin-stimulated cAMP formation in human mGlu2- and mGlu3-expressing cells. In slices of the adult rat hippocampus 2R,4R-APDC had no effect on basal phosphoinositide hydrolysis; however, it was found to greatly enhance phosphoinositide hydrolysis to DHPG or quisqualate. In the neonatal rat hippocampus, 2R,4R-APDC enhanced the potency of DHPG, while not affecting the maximal response to group 1 mGlu receptor agonists. Thus, the phosphoinositide response in the rat hippocampus to 1S,3R-ACPD is mediated by a synergistic interaction between group 1 and group 2 mGlu receptors.
Similar articles
-
Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4- dicarboxylate.Neuropharmacology. 1995 Aug;34(8):843-50. doi: 10.1016/0028-3908(95)00061-a. Neuropharmacology. 1995. PMID: 8532165
-
(1 S,3 R)-1-aminocyclopentane-1,3-dicarboxylic acid-induced increases in cyclic AMP formation in the neonatal rat hippocampus are mediated by a synergistic interaction between phosphoinositide- and inhibitory cyclic AMP-coupled mGluRs.J Neurochem. 1996 May;66(5):1981-5. doi: 10.1046/j.1471-4159.1996.66051981.x. J Neurochem. 1996. PMID: 8780026
-
Regulation of phosphoinositide turnover in neonatal rat cerebral cortex by group I- and II- selective metabotropic glutamate receptor agonists.Br J Pharmacol. 1998 Feb;123(3):581-9. doi: 10.1038/sj.bjp.0701626. Br J Pharmacol. 1998. PMID: 9504400 Free PMC article.
-
Glutamate metabotropic receptors as targets for drug therapy in epilepsy.Eur J Pharmacol. 2003 Aug 22;476(1-2):3-16. doi: 10.1016/s0014-2999(03)02149-6. Eur J Pharmacol. 2003. PMID: 12969743 Review.
-
(S)-3,5-DHPG: a review.CNS Drug Rev. 2002 Spring;8(1):101-16. doi: 10.1111/j.1527-3458.2002.tb00218.x. CNS Drug Rev. 2002. PMID: 12070529 Free PMC article. Review.
Cited by
-
Interactions between ephrin-B and metabotropic glutamate 1 receptors in brain tissue and cultured neurons.J Neurosci. 2005 Mar 2;25(9):2245-54. doi: 10.1523/JNEUROSCI.4956-04.2005. J Neurosci. 2005. PMID: 15745950 Free PMC article.
-
The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies.Curr Neuropharmacol. 2016;14(5):455-73. doi: 10.2174/1570159x13666150421003225. Curr Neuropharmacol. 2016. PMID: 27296640 Free PMC article. Review.
-
Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C-dependent mechanism in pyramidal neurones of rat prefrontal cortex.J Physiol. 2004 Feb 1;554(Pt 3):765-77. doi: 10.1113/jphysiol.2003.056812. Epub 2003 Nov 28. J Physiol. 2004. PMID: 14645456 Free PMC article.
-
Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.Neuropharmacology. 2021 Sep 15;196:108687. doi: 10.1016/j.neuropharm.2021.108687. Epub 2021 Jun 25. Neuropharmacology. 2021. PMID: 34175327 Free PMC article. Review.
-
Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system.Neuropharmacology. 2018 Jan;128:301-313. doi: 10.1016/j.neuropharm.2017.10.026. Epub 2017 Oct 25. Neuropharmacology. 2018. PMID: 29079293 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases